Breathe Well Live Well
cleveland.com |
Chronic asthma common in toddlers: Meet Santana and Serenity (photos, video)
cleveland.com Asthma attacks are heartbreakingly routine in their homes. No matter how many they've lived through, each is equally terrifying. Barnes calls the ambulance for her 3-year-old son Santana Hudson. Burgan bundles her 4-year-old daughter Serenity into the car. |
View full post on asthma – Google News
cleveland.com |
Cleveland sisters with chronic asthma: Meet Beautifull and Gorgeous (photos)
cleveland.com CLEVELAND, Ohio — In Nechole Jennings' Broadway-Slavic Village home on the city's East Side, each asthma inhaler is marked with initials. With three asthmatic grandchildren to care for, it's a necessity. Beautifull Foster, 10; Gorgeous Lloyd, 8; and … |
View full post on asthma – Google News
 |
Why use long acting bronchodilators in chronic obstructive lung diseases? An extensive review on formoterol and salmeterol.
Eur J Intern Med. 2015 Jun 3;
Authors: Santus P, Radovanovic D, Paggiaro P, Papi A, Sanduzzi A, Scichilone N, Braido F
Abstract
Long-acting ?2-adrenoceptor agonists, formoterol and salmeterol, represent a milestone in the treatments of chronic obstructive lung diseases. Although no specific indications concerning the choice of one molecule rather than another are provided by asthma and COPD guidelines, they present different pharmacological properties resulting in distinct clinical employment possibilities. In particular, salmeterol has a low intrinsic efficacy working as a partial receptor agonist, while formoterol is a full agonist with high intrinsic efficacy. From a clinical perspective, in the presence of low ?2-adrenoceptors availability, like in inflamed airways, a full agonist can maintain its bronchodilatory and non-smooth muscle activities while a partial agonist may be less effective. Furthermore, formoterol presents a faster onset of action than salmeterol. This phenomenon, combined with the molecule safety profile, leads to a prompt amelioration of the symptoms, and allows using this drug in asthma as an “as needed” treatment in patients already on regular treatment. The fast onset of action and the full agonism of formoterol need to be considered in order to select the best pharmacological treatment of asthma and COPD.
PMID: 26049917 [PubMed – as supplied by publisher]
View full post on pubmed: asthma
Wgnsradio |
May is Asthma Awareness Month: Managing Chronic Disease
Wgnsradio May is National Asthma Awareness Month and more than seven-thousand Tennesseans were hospitalized for asthma in 2010, the most recent data available. NewsRadio WGNS' Stephanie Carson has more on how asthma can be treated and prevented. Environmental factors play role in spread of asthma: Experts |
View full post on asthma – Google News
Condition: Psoriasis
Intervention: Drug: Atorvastatin
Sponsor: Philippine Dermatological Society
Completed – verified April 2015
View full post on ClinicalTrials.gov: asthma | received in the last 14 days
|
Allergic rhinitis without asthma and chronic bronchitis
Medscape Conclusions The impact of asthma, chronic bronchitis and allergic rhinitis on all-cause hospitalizations and limitations in daily activities is substantial, and it is markedly different among adults from the general population in Italy. The … |
View full post on asthma – Google News
Conditions: Asthma; Chronic Obstructive Pulmonary Disease (COPD)
Intervention: Drug: Marketed antagonists
Sponsor: Teva Pharmaceuticals Europe
Not yet recruiting – verified April 2015
View full post on ClinicalTrials.gov: asthma | received in the last 14 days
Chronic disease prevalence in women and air pollution – A 30-year longitudinal cohort study.
Environ Int. 2015 Apr 6;80:26-32
Authors: To T, Zhu J, Villeneuve PJ, Simatovic J, Feldman L, Gao C, Williams D, Chen H, Weichenthal S, Wall C, Miller AB
Abstract
BACKGROUND: Air pollution, such as fine particulate matter (PM2.5), can increase risk of adverse health events among people with heart disease, diabetes, asthma and chronic obstructive pulmonary disease (COPD) by aggravating these conditions. Identifying the influence of PM2.5 on prevalence of these conditions may help target interventions to reduce disease morbidity among high-risk populations.
OBJECTIVES: The objective of this study is to measure the association of exposure of PM2.5 with prevalence risk of various chronic diseases among a longitudinal cohort of women.
METHODS: Women from Ontario who enrolled in the Canadian National Breast Screening Study (CNBSS) from 1980 to 1985 (n=29,549) were linked to provincial health administrative data from April 1, 1992 to March 31, 2013 to determine the prevalence of major chronic disease and conditions (heart disease, diabetes, asthma, COPD, acute myocardial infarction, angina, stroke and cancers). Exposure to PM2.5 was measured using satellite data collected from January 1, 1998 to December 31, 2006 and assigned to resident postal-code at time of entry into study. Poisson regression models were used to describe the relationship between exposure to ambient PM2.5 and chronic disease prevalence. Prevalence rate ratios (PRs) were estimated while adjusting for potential confounders: baseline age, smoking, BMI, marital status, education and occupation. Separate models were run for each chronic disease and condition.
RESULTS: Congestive heart failure (PR=1.31, 95% CI: 1.13, 1.51), diabetes (PR=1.28, 95% CI: 1.16, 1.41), ischemic heart disease (PR=1.22, 95% CI: 1.14, 1.30), and stroke (PR=1.21, 95% CI: 1.09, 1.35) showed over a 20% increase in PRs per 10?g/m(3) increase in PM2.5 after adjusting for risk factors. Risks were elevated in smokers and those with BMI greater than 30.
CONCLUSIONS: This study estimated significant elevated prevalent rate ratios per unit increase in PM2.5 in nine of the ten chronic diseases studied.
PMID: 25863281 [PubMed – as supplied by publisher]
View full post on pubmed: asthma
 |
Are the Diagnostic Criteria for Asthma-COPD Overlap Syndrome Appropriate in Biomass Smoke-Induced chronic obstructive pulmonary disease?
Arch Bronconeumol. 2015 Mar 19;
Authors: Golpe R, Pérez de Llano L
PMID: 25799499 [PubMed – as supplied by publisher]
View full post on pubmed: asthma
Condition: Asthma
Intervention: Device: CPAP vs Sham CPAP
Sponsors: Indiana University; National Heart, Lung, and Blood Institute (NHLBI)
Recruiting – verified March 2015
View full post on ClinicalTrials.gov: asthma | received in the last 14 days